ELI LILLY Aktie

 

Eli Lilly wins CHMP backing to expand Olumiant use in adolescents with severe alopecia areata, with the EU approval decision expected shortly....

Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way....

Novo Nordisk is investing in a facility in Ireland as it expands its production capacities of the newly launched Wegovy pill, the Danish drugmaker said Monday....

Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings. The Earnings Machine Lilly closed 2025 with back-to-back blowout quarters. Q4 revenue hit $19.29 billion against a consensus estimate of $18.14 billion, while non-GAAP EPS of $7.54 cleared ... What Smart Money Loves About Lilly The post What Smart Money Loves About Lilly appeared first on 24/7 Wall St.....

Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock....

Pharma - Nach dem jüngsten Debakel bei Novo Nordisk sehen Analysten die Vormachtstellung von Eli Lilly im Markt von Abnehmmedikamenten zementiert....

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for O......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) on Thursday reported positive results from its Phase 3 ACHIEVE-3 trial evaluating orforglipron in adults with type 2 diabetes inadequately cont......

Daily orforglipron tablets led to greater weight loss than semaglutide tablets, offering potential oral alternative to Wegovy and MounjaroA new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for a non-injection alternative to Wegovy and Mounjaro.The drug, called orforglipron and manufactured by Eli Lilly, is prescribed for type 2 diabetes and targets the same GLP-1 receptors as oral semaglutide. Like semaglutide, it lowers blood sugar levels, slows digestion and suppresses appetite. However, unlike semaglutide tablets, it does not need to be taken on an empty stomach. Continue reading......

Das dänische Pharmaunternehmen heizt den Wettbewerb mit dem US-Konkurrenten Eli Lilly weiter an. Novo Nordisk senkt die Preise etwa für die Adipositas-Therapie Wegovy um rund die Hälfte....

Eli Lilly has seen revenue and earnings soar in recent years....

Charlotte (www.aktiencheck.de) - Eli Lilly-Aktienanalyse von BofA Securities: Die Analysten von BofA Securities stufen die Aktie von Eli Lilly and Company (ISIN: US5324571083, WKN: 858560, Ticker-Symbol: LLY, NYSE-Symbol: LLY) weiterhin mit "buy" ein. Die heutige Ankündigung von Novo Nordisk (NVO), die Listenpreise für GLP-1-Präparate zu senken, sorge zwar für eine aufmerksamkeitsstarke Schlagzeile, habe nach Einschätzung von BofA jedoch voraussichtlich keine wesentlichen Auswirkungen auf den US-Markt. [mehr]...

The pharma giant's multibillion deal resets the CAR-T landscape....

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base....

Frankfurt (www.aktiencheck.de) - Novo Nordisk-Aktienanalyse von XTB: Jens Klatt, Marktanalyst bei XTB, nimmt die Aktie Novo Nordisk A/S (ISIN: DK0062498333, WKN: A3EU6F, Ticker-Symbol: NOV, NASDAQ Kopenhagen-Symbol: NOVO B) unter die Lupe. Die Novo Nordisk Aktie habe einen massiven Kurseinbruch von über 15% erlebt und sei auf den tiefsten Stand seit Juni 2021 gefallen. [mehr]...

Novo Nordisk will ab 2027 die Preise für seine Blockbuster-Medikamente Wegovy und Ozempic in den USA drastisch senken und setzt damit Wettbewerber Eli Lilly unter Zugzwang. Die Aktien der beiden Pharmakonzerne gaben daraufhin nach....

Investors worried that the company could take quite a revenue hit due to a competitor's move....

The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly's Zepbound....